Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Sangamo Therapeutics

Main focus: Gene editing using zing-finger nucleases for novel gene-ediing and cell therapies.

Company stage: Clinical

Diseases: Solid graft transplantations, beta-thalassemia, sickle cell disease, inflammatory bowel disease, multiple sclerosis, solid tumours, haematological cancers

Genome editing technology: Zinc finger nucleases (ZNFs)

Funding stage: Public (NASDAQ:SGMO)

Location: South San Francisco, CA, USA



Partners: Sanofi, Takeda Pharma, Novartis, Pfizer, Kite Pharma, Biogen

Sangamo Therapeutics is the only company solely focused on the development of zinc finger nucleases (ZFNs) as a tool for genetic engineering. The company applies the tool for both ex vivo and in vivo-based gene-editing therapies, as well as a tool for genome regulation. The company is currently sponsoring clinical trials for sickle cell disease and beta-thalassemia, where ZFNs are applied for gene editing. The company holds multiple substantial collaborations with companies such Pfizer, Biogen, Novartis, Takeda, Sanofi and Kite Pharma.


HashtagSangamo Therapeutics Inc.

Company: Sangamo Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine